​

UroGen Pharma (URGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

URGN Stock Forecast

UroGen Pharma (URGN) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $23.50, with a high of $31.00 and a low of $16.00. This represents a 25.07% increase from the last price of $18.79.

$10 $15 $20 $25 $30 $35 High: $31 Avg: $23.5 Low: $16 Last Closed Price: $18.79

URGN Stock Rating

UroGen Pharma stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (73.33%), 4 Hold (26.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 4 11 0 Strong Sell Sell Hold Buy Strong Buy

URGN Price Target Upside V Benchmarks

TypeNameUpside
StockUroGen Pharma25.07%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts-23
Avg Price Target-$23.50$24.00
Last Closing Price$18.79$18.79$18.79
Upside/Downside-25.07%27.73%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25241--7
Aug, 25251--8
Jul, 25251--8
Jun, 25152--8
May, 25151--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 13, 2025Paul ChoiGoldman Sachs$16.00$12.0333.00%-14.85%
Jun 13, 2025Leland GershellOppenheimer$31.00$12.03157.69%64.98%
Oct 14, 2024Jason KolbertEF Hutton$25.00$12.6098.41%33.05%
Jun 14, 2024Stephen RichardsonEvercore ISI$46.00$20.26127.05%144.81%
Jun 14, 2024Leland GershellOppenheimer$40.00$17.50128.57%112.88%
Jun 14, 2024Raghuram SelvarajuH.C. Wainwright$60.00$17.50242.86%219.32%
Jun 14, 2024Paul ChoiGoldman Sachs$22.00$17.5025.71%17.08%
May 14, 2024Leland GershellOppenheimer$32.00$13.07144.84%70.30%
Mar 15, 2024Leland GershellOppenheimer$34.00$14.46135.13%80.95%
Dec 12, 2022H.C. Wainwright$23.00$7.94189.67%22.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 18, 2025Piper SandlerOverweightinitialise
Jun 16, 2025H.C. WainwrightNeutralBuyupgrade
Jun 13, 2025Goldman SachsNeutralNeutralhold
Jun 13, 2025OppenheimerOutperformBuyinitialise
Jun 13, 2025ScotiabankOutperformOutperformhold
Jun 13, 2025GuggenheimBuyBuyhold
May 22, 2025H.C. WainwrightBuyNeutraldowngrade
May 16, 2025Cowen & Co.BuyBuyhold
Oct 16, 2024OppenheimerOutperformOutperformhold
Oct 14, 2024EF HuttonBuyinitialise

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.90$-4.96$-4.79$-3.55$-2.96----
Avg Forecast$-5.92$-4.82$-4.52$-3.56$-3.14$-2.68$-0.44$2.54$3.80
High Forecast$-4.92$-4.01$-4.03$-3.45$-3.05$-1.84$2.91$4.36$4.38
Low Forecast$-6.73$-5.48$-5.01$-3.64$-3.23$-4.15$-6.48$0.80$3.29
Surprise %-0.34%2.90%5.97%-0.28%-5.73%----

Revenue Forecast

$0 $130M $260M $390M $520M $650M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.80M$48.04M$64.36M$82.71M$90.40M----
Avg Forecast$11.51M$48.11M$64.78M$81.75M$90.94M$133.00M$274.70M$494.08M$579.86M
High Forecast$12.72M$53.16M$70.22M$82.20M$91.75M$142.82M$277.16M$552.35M$648.24M
Low Forecast$10.02M$41.85M$59.38M$81.30M$90.12M$123.19M$272.24M$443.44M$520.42M
Surprise %2.48%-0.13%-0.66%1.18%-0.59%----

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-128.48M$-110.82M$-109.16M$-102.24M$-126.87M----
Avg Forecast$-170.74M$-139.03M$-130.28M$-102.24M$-90.50M$-115.51M$25.79M$74.39M$109.47M
High Forecast$-141.88M$-115.54M$-116.15M$-99.57M$-87.87M$-52.96M$83.81M$125.72M$126.26M
Low Forecast$-194.08M$-158.04M$-144.50M$-105.09M$-93.13M$-119.77M$-186.90M$23.07M$94.89M
Surprise %-24.75%-20.29%-16.21%-40.19%----

URGN Forecast FAQ

Is UroGen Pharma stock a buy?

UroGen Pharma stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that UroGen Pharma is a favorable investment for most analysts.

What is UroGen Pharma's price target?

UroGen Pharma's price target, set by 15 Wall Street analysts, averages $23.5 over the next 12 months. The price target range spans from $16 at the low end to $31 at the high end, suggesting a potential 25.07% change from the previous closing price of $18.79.

How does UroGen Pharma stock forecast compare to its benchmarks?

UroGen Pharma's stock forecast shows a 25.07% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and underperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for UroGen Pharma over the past three months?

  • September 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is UroGen Pharma’s EPS forecast?

UroGen Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.68, marking a -9.46% decrease from the reported $-2.96 in 2024. Estimates for the following years are $-0.44 in 2026, $2.54 in 2027, and $3.8 in 2028.

What is UroGen Pharma’s revenue forecast?

UroGen Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $133M, reflecting a 47.13% increase from the reported $90.4M in 2024. The forecast for 2026 is $274.7M, followed by $494.08M for 2027, and $579.86M for 2028.

What is UroGen Pharma’s net income forecast?

UroGen Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-116M, representing a -8.96% decrease from the reported $-127M in 2024. Projections indicate $25.79M in 2026, $74.39M in 2027, and $109.47M in 2028.